Adial Pharmaceuticals, Inc.
ADIL
Rank in Stocks
#26762
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the... Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Share Price
$4.00
Last synced: 2026-11-06
Market Cap
$18.49M
Change (1 day)
7.82%
Change (1 year)
-51.52%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Adial Pharmaceuticals, Inc. (ADIL)
Category
Healthcare
EPS for Adial Pharmaceuticals, Inc. (ADIL)
EPS as of June 2026 TTM: $-16.53
According to Adial Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-16.53. At the end of 2025 the company had an EPS of $-11.93, an increase over its 2024 EPS of $-17.75.
EPS history for Adial Pharmaceuticals, Inc. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-16.53 | 38.56% |
| 2025 | $-11.93 | -32.79% |
| 2024 | $-17.75 | -86.95% |
| 2023 | $-136.00 | -54.59% |
| 2022 | $-299.50 | -54.13% |
| 2021 | $-653.00 | 19.87% |
| 2020 | $-544.75 | -0.05% |
| 2019 | $-545.00 | -64.32% |
| 2018 | $-1.53K | 1,075.00% |
| 2017 | $-130.00 | 136.36% |
| 2016 | $-55.00 | -48.60% |
| 2015 | $-107.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -194.74% |
US
|
|
| $-7.07 | -57.23% |
US
|
|
| $-5.29 | -68.00% |
AU
|
|
| $12.88 | -177.92% |
BE
|
|
| $21.56 | -230.43% |
NL
|
Questions about Adial Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Adial Pharmaceuticals, Inc.'s earnings per share (EPS)?
Adial Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-16.53, as of Jun 2026.
What was Adial Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Adial Pharmaceuticals, Inc.'s earnings per share (EPS) was $-11.93, compared with $-17.75 in 2024.
How has Adial Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Adial Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-11.93) and lowest in 2021 ($-653.00).
How does Adial Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Adial Pharmaceuticals, Inc.'s earnings per share (EPS) ($-16.53) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.